Logo

Pfizer to Use ActivX Technology in Drug Discovery, Proteomic Profiling

Feb 09, 2005

NEW YORK, Feb. 9 (GenomeWeb News) - Pfizer researchers will use ActivX's high-throughput protein analysis in drug discovery, proteomic profiling, compound selectivity, and other projects, ActivX said today.

 

ActivX Biosciences, a subsidiary of Tokyo-based Kyorin Pharmaceuticals, also said that it and the drug giant will collaborate on multiple future projects.

 

Financial details of the agreement, which is part of an expanding partnership between the two companies, included an upfront technology access fee, along with research support payments by Pfizer.

 

As GenomeWeb News reported earlier this month, ActivX was acquired by Kyorin Pharameceuticals. The company paid $21 million for the proteomics shop which it wholly owns and plans to use as its USdrug-discovery and development center.

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.